10-K: Dalrada Faces Going Concern Doubt Amidst Losses, Debt

Dalrada Financial Corporation reports recurring losses and negative working capital, raising substantial doubt about its ability to continue as a going concern, despite some revenue growth in key segments.

Summary

• Total revenues increased by 2.3% to $20,302,803 for the year ended June 30, 2025, from $19,842,419 in the prior year.
• Gross profit significantly improved by 438.7% to $5,301,122 in 2025, compared to $984,032 in 2024.
• Net loss decreased by 15.5% to $(24,672,190) in 2025, from $(29,185,898) in 2024.
• The company reported negative working capital of $(8,001,819) as of June 30, 2025, worsening from $(7,085,306) in 2024.
• Cash used in operating activities increased to $(17,972,434) in 2025, from $(7,873,760) in 2024.
• Total stockholders' equity shifted to a deficit of $(6,688,417) in 2025, from a positive equity of $3,346,107 in 2024.
• An impairment loss of $2,735,540 on goodwill was recorded in 2025, primarily related to Deposition Technology.
• Genefic segment revenue decreased by 21.1% to $10,424,584, mainly due to a shift in pharmacy sales model, but IV Services and Dalrada Career Institute showed significant growth.
• Dalrada Climate Technology segment revenue increased by 188.17% to $8,081,063, driven by Dalrada Energy Services and Bothof Brothers Construction, and the acquisition of Grand Entrances.
• Dalrada Precision Manufacturing segment revenue decreased by 81.7% to $448,409, primarily due to the loss of a primary customer for Precision Parts and reduced operations for Ignite.
• Dalrada Technologies segment revenue decreased by 1.8% to $1,348,747 due to several contracts ending.
• Corporate expenses decreased by 18.8% due to centralization of resources.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by recurring losses, negative working capital, and an explicit 'going concern' warning from auditors. While some segments show revenue growth, others are declining, and the overall financial health is poor. Significant debt conversions, ongoing legal issues, and identified material weaknesses in internal controls further underscore the high risk and negative outlook.

Positives

• Total revenues increased by 2.3% year-over-year, reaching $20,302,803.
• Gross profit saw a substantial increase of 438.7% to $5,301,122.
• Net loss improved by 15.5%, reducing to $(24,672,190) from $(29,185,898).
• Loss from operations improved by 23.8% to $(20,458,710).
• Dalrada Climate Technology segment revenue grew by 188.17%, driven by strong performance from Dalrada Energy Services (260.7% increase) and Bothof Brothers Construction (73.8% increase).
• IV Services revenue within the Genefic segment increased by 696.59% due to a full year of operation.
• Dalrada Career Institute's revenue increased by 48.9% due to LVN accreditation and rising student enrollment.
• Corporate operating expenses decreased by 18.8% due to the centralization of resources, contributing to overall cost savings.

Negatives

• The company has recurring losses from operations and a net capital deficiency, raising substantial doubt about its ability to continue as a going concern.
• Negative working capital worsened to $(8,001,819) in 2025 from $(7,085,306) in 2024.
• Net cash used in operating activities significantly increased to $(17,972,434) in 2025 from $(7,873,760) in 2024, indicating higher cash burn.
• Total stockholders' equity shifted from positive $3,346,107 in 2024 to a deficit of $(6,688,417) in 2025.
• An impairment loss of $2,735,540 on goodwill was recorded in 2025, primarily related to the Deposition Technology business.
• Genefic segment revenue decreased by 21.1%, with Genefic Specialty Pharmacy revenue decreasing by 51.9% due to a shift in sales model and high debt service.
• Dalrada Precision Manufacturing segment revenue decreased sharply by 81.7%, largely due to the loss of a primary customer for Dalrada Precision Parts (95.6% decrease) and ramping down of Ignite operations (70.0% decrease).
• Dalrada Climate Technology experienced delays in commercializing its proprietary DCT-1 heat pump and ramping up its residential heat pump platform, while facing high operating costs.
• Material weaknesses in internal control over financial reporting were identified as of June 30, 2025, regarding financial reporting schedules, revenue recognition, allowance estimates, and the lack of a comprehensive policies manual.
• The company is involved in numerous ongoing legal proceedings, including several breach of contract and fraud allegations.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses and negative working capital.
• The company's ability to meet financial obligations is dependent on successful financing through equity and/or debt investors, and growing profitable subsidiaries, which cannot be guaranteed.
• Cybersecurity threats are faced in the ordinary course of business, and while past incidents have not been material, future incidents could have a material adverse effect.
• The company is exposed to various legal proceedings, including breach of contract, fraud, and labor law violations, which could result in significant liabilities and costs.
• Reliance on estimates in financial reporting, such as revenue recognition, inventory valuation, and goodwill impairment, means actual results could differ materially and adversely from estimates.
• Changes in the fair value of contingent earn-out consideration related to acquisitions could cause material impact and volatility in operating results.
• The company's EIDL loan is technically in default due to a change in ownership without SBA consent, posing a risk of acceleration or other penalties.
• Inability to raise additional capital on acceptable terms could have a material adverse effect on business, prospects, results of operations, liquidity, and financial condition.
• Future equity or convertible securities issuances could result in substantial dilution to existing stockholders.

Future Outlook

The company anticipates incurring additional expenses on research and development over the next 12 months. Management plans to achieve cost savings and other strategic objectives to address profitability by focusing on growing the most profitable subsidiaries and reducing investments in areas not expected to have long-term benefits. Specific initiatives include finishing percentage of completion projects for DepTec, entering more construction contracts through Bothof Brothers, ramping up the new specialty pharmacy business model, and pursuing partnerships to expedite the commercialization of the DCT-1 heat pump. Operational liquidity is expected to be obtained through collection of outstanding accounts receivable, heat pump sales, and ongoing projects.

Management Comments

• Management is implementing plans to achieve cost savings and other strategic objectives to address Company profitability.
• The Company continues to focus on growing the subsidiaries anticipated to be most profitable while reducing investments in areas that are not expected to have long-term benefits.
• The Company will continue to pursue synergistic opportunities to enhance its business portfolio.
• We cannot be certain that our plans and initiatives would be effectively implemented within one year after the filing date of this report.
• Without giving effect to the prospect of raising additional capital, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond our control, it is unlikely that we will be able to generate sufficient cash flows to meet our required financial obligations, including our debt service and other obligations due to third parties.

Industry Context

The company operates across diverse markets including specialty pharmaceutical and infusion, healthcare education, heat pump technology, deposition technology, and energy services. The specialty pharmaceutical and infusion market is growing due to an aging population and chronic diseases. Healthcare education is driven by technology and demand for skilled workers. The heat pump market is expanding due to decarbonization efforts and government incentives. Deposition technology is seeing robust growth from semiconductor and electronics demand. The company's strategy of transformative innovation and sustainable solutions aligns with global trends addressing climate change and healthcare gaps.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Asset Group, Inc. filed a breach of contract lawsuit against Dalrada Health Products (DHP) in September 2023, alleging DHP lacked authority to sell face masks. DHP is preparing a Cross-Complaint for $3,240,000 for Asset's material breach, with a jury trial scheduled for April 2026.
• MDIQ filed a breach of contract lawsuit against Dalrada Financial Corporation (DFCO) in March 2024 for unpaid invoices, despite MDIQ's alleged failure to process insurance claims for COVID-19 testing. DFCO is counter-suing for approximately $2,000,000.
• DFCO filed a lawsuit against DePrey Company and Simon Gray in July (year not specified, but recent) for breach of contract and intentional interference with contractual relationships related to misappropriating Fastenal Company purchase orders.
• DFCO filed a lawsuit in June 2024 against Stuart Cox for fraud, breach of contract, and unjust enrichment related to the acquisition of Likido company, alleging failure to disclose pertinent financial liabilities. A motion to vacate the settlement agreement has been filed by Mr. Cox.
• DFCO filed a lawsuit on November 19, 2024, against William Bonar, Samantha and Ian MacKenzie, Jillian Hughes, and Marion Bonar for fraud, tortious interference, and misappropriation of trade secrets, involving former employees/directors of DFCO's UK subsidiaries.
• FFF Enterprises filed a lawsuit on November 27, 2024, against Genefic, Inc. and DFCO for an alleged breach of a service agreement with a demand for $564,743.48. The case has been settled with no further liability owed.
• A former employee filed a complaint on June 20, 2024, alleging numerous labor law violations after being laid off. A jury trial is scheduled for October 10, 2025.
• Lamie RB Investments, LLC filed a suit on March 27, 2025, for breach of a lease contract with Genefic, Inc., seeking damages equal to the lease term. Genefic, Inc. filed a motion to dismiss.
• The Company filed a lawsuit against Wells Fargo on July 7, 2025, for releasing Pala funds while the account was frozen for litigation.
• Dalrada Precision Manufacturing Inc. filed a complaint on August 11, 2025, against Global Resources Sustainability Group, LLC and Richard Abernathy for fraud, conversion, breach of contract, and violation of Bus. & Prof. Code 17200.

Related Party Transactions

• Received $16,473,716 in cash funding or expenses paid on behalf of the company from related parties (corporations owned and/or operated by an individual with a familial relationship with the CEO) during the year ended June 30, 2025.
• Bothof Brothers and Grand Entrances subsidiaries recognized $1,602,577 and $77,896, respectively, in revenue from related parties during the year ended June 30, 2025.
• Formalized an employment agreement with the Chief Executive Officer on July 1, 2024, entitling him to $800,000 per year, potential 10% ownership post reverse split, a $50,000 quarterly bonus, and $250,000 annually in cashless warrants.
• Notes Payable Related Parties had an outstanding principal of $1,701,415 as of June 30, 2025, with accrued interest of $170,444.
• Converted $11,861,578 of related party debt principal and interest into 14,205 shares of Series I Convertible Preferred Stock on June 25, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing equity issuances and conversions of related party debt into preferred stock.
• Shareholders are exposed to substantial financial risk due to recurring losses, negative working capital, and the 'going concern' doubt.
• Employees may be impacted by cost-cutting measures and potential restructuring, as indicated by the layoff of several employees mentioned in a legal proceeding.
• Customers and suppliers may face uncertainty due to the company's financial instability and numerous legal disputes.
• Creditors are exposed to risk given the company's substantial debt, negative working capital, and reliance on future financing to meet obligations.

Next Steps

• Achieve cost savings and other strategic objectives to address company profitability.
• Focus on growing the most profitable subsidiaries and reducing investments in less beneficial areas.
• Pursue synergistic opportunities to enhance the business portfolio.
• Finish percentage of completion projects for DepTec.
• Enter more construction contracts through Bothof Brothers Construction.
• Ramp up the new specialty pharmacy business model.
• Pursue partnerships to help expedite the commercialization of the DCT-1 heat pump.
• Obtain operational liquidity through collection of outstanding accounts receivable from medical insurance providers, Medicare, pharmaceutical sales, and heat pump sales.
• Remediate identified material weaknesses in internal control over financial reporting by standardizing reconciliation processes, enhancing revenue recognition procedures, and engaging outside advisors for complex transactions.
• File the income tax return for the year ended June 30, 2025, which is currently on extension.
• Jury trial for former employee's labor law complaint scheduled for October 10, 2025.
• Jury trial for Asset Group, Inc. vs. Dalrada Health Products scheduled for April 2026.
• IV Services, LLC lease amended to extend term through September 31, 2030.

Key Dates

Recommendation

Dalrada Financial Corporation presents an extremely high-risk investment profile. The company's auditors have raised 'substantial doubt' about its ability to continue as a going concern, a critical red flag. It consistently reports significant net losses and negative working capital, indicating a severe lack of liquidity and profitability. While some segments show revenue growth, others are in sharp decline, and the overall cash burn from operations is increasing. The company relies heavily on debt and equity financing, leading to potential significant dilution for existing shareholders. Furthermore, identified material weaknesses in internal controls and a multitude of ongoing legal proceedings add layers of operational and financial uncertainty. Given these severe and pervasive financial and operational challenges, a seasoned investor would likely recommend a 'strong sell' to mitigate exposure to a company facing existential threats.

Keywords

Dalrada Financial Corporation, DFCO, SEC 10-K, Financial Report, Going Concern, Net Loss, Revenue Growth, Healthcare Solutions, Climate Technology, Precision Manufacturing, Digital Engineering, Specialty Pharmacy, Heat Pumps, Semiconductor Industry, Corporate Governance, Legal Proceedings, Related Party Transactions, Stock-Based Compensation, Internal Controls